New Asthma Inhalant Backed for FDA Approval
New Asthma Inhalant Backed for FDA Approval
Advair would be available for patients aged 12 and over. It provides a twice-daily single inhalation of the two drugs.
FDA often follows, but is not bound by, the recommendations of its advisory committees.
The agency would be required to make an approval decision on the drug by next March, but Shah tells WebMD that broader agency initiatives on the regulation of inhaled drugs may push that decision back to the middle of next year.
New Asthma Inhalant Backed for FDA Approval
Advair would be available for patients aged 12 and over. It provides a twice-daily single inhalation of the two drugs.
FDA often follows, but is not bound by, the recommendations of its advisory committees.
The agency would be required to make an approval decision on the drug by next March, but Shah tells WebMD that broader agency initiatives on the regulation of inhaled drugs may push that decision back to the middle of next year.
Source...